Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RHYTHM PHARMACEUTICALS, INC.

(RYTM)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
28.32 USD   +4.89%
12/01Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
GL
12/01Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
AQ
11/22Rhythm Pharmaceuticals Announces IMCIVREE Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rhythm Pharmaceuticals Prices Common Stock Offering at $26 Per Share

09/15/2022 | 03:08am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
RHYTHM PHARMACEUTICALS, INC. 4.89% 28.32 Delayed Quote.183.77%
WELLS FARGO & COMPANY -1.98% 45.94 Delayed Quote.-4.25%
All news about RHYTHM PHARMACEUTICALS, INC.
12/01Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conf..
GL
12/01Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conf..
AQ
11/22Rhythm Pharmaceuticals Announces IMCIVREE Granted Marketing Authorization in Great Brit..
AQ
11/21Rhythm Pharmaceuticals Announces ▼IMCIVREE« (setmelanotide) Granted Marketing Aut..
GL
11/21Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorizat..
CI
11/09Morgan Stanley Adjusts Price Target on Rhythm Pharmaceuticals to $26 From $16, Maintain..
MT
11/08RHYTHM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/08Rhythm Pharmaceuticals Q3 Loss Widens, Beats Wall Street Forecast, Revenue Rises; Share..
MT
11/08Rhythm Pharmaceuticals : Q3 2022 Earnings Conference Call Presentation
PU
11/08Transcript : Rhythm Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 08, 202..
CI
More news
Analyst Recommendations on RHYTHM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 21,7 M - -
Net income 2022 -186 M - -
Net cash 2022 245 M - -
P/E ratio 2022 -7,95x
Yield 2022 -
Capitalization 1 596 M 1 596 M -
EV / Sales 2022 62,3x
EV / Sales 2023 22,8x
Nbr of Employees 140
Free-Float 99,7%
Chart RHYTHM PHARMACEUTICALS, INC.
Duration : Period :
Rhythm Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHYTHM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 28,32 $
Average target price 33,44 $
Spread / Average Target 18,1%
EPS Revisions
Managers and Directors
David P. Meeker Chairman, President & Chief Executive Officer
Hunter C. Smith President, CEO, CFO, Secretary & Treasurer
Joseph Shulman Chief Technical Officer
Brieana Buckley Vice President-Medical Affairs
Linda Shapiro Manning Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RHYTHM PHARMACEUTICALS, INC.183.77%1 596
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.20.54%81 852
BIONTECH SE-34.16%41 250
WUXI APPTEC CO., LTD.-34.47%32 173
GENMAB A/S24.60%30 178